CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 126 enrolled
Drug / intervention
Shi-Bi-Lin +1 moredrug
Likely dose
Shi-Bi-Lin 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00456755
NCT00456755Phase 2Completed

A Herbal Formula (SBL) for the Treatment of Perennial Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial

Chinese University of Hong Kong·interventional·Posted Apr 5, 2007·Updated Jan 6, 2010

In Brief

A Phase 2 clinical trial evaluating Shi-Bi-Lin and Placebo for Perennial Allergic Rhinitis. Completed, enrolled 126 participants across 2 sites.

Detailed Summary

Allergic rhinitis(AR) is one of the most common allergic disorders throughout the world.The conventional therapies are effective in alleviating symptoms but the efficacy are limited and not persistent. Furthermonre, the cost and side-effect are known defects. A classical Chinese herbal formula, has been used for AR for centries. Our study purpose is to evaluate the clinical efficacy and safety of this formula verus placebo in perennial allergic rhinitis (PAR). Hypothesis: the classical herbal formula would improve the symptoms of PAR patients and change some immunological parameters in the peripheral blood when comparing with the placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 5, 2007
Enrollment StartMar 1, 2004
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.2 years ago

Interventions

Shi-Bi-Lindrug

4 weeks of treatment, dose of 1 g (two capsules), twice daily

Placeboother

4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily